CARDIOFLOW-B (02160) has issued approximately 3.954 billion shares of bonus shares.
Heart Communication Medical -B (02160) announced that it will complete the issuance of approximately 3.954 billion shares of consideration shares on December 19, 2025, with an issuance price of HK$1.35 per share.
CARDIOFLOW-B (02160) announced that it completed the issuance of approximately 3.954 billion shares of cost shares on December 19, 2025, with an issuance price of HK$1.35 per share.
Related Articles
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
